# Doxycycline Post-Exposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infections

## Updates, Authorship, and Related Guidelines

<table>
<thead>
<tr>
<th>Date of current publication</th>
<th>September 25, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intended users</td>
<td>New York State clinicians who provide medical care for individuals at risk of acquiring sexually transmitted infections</td>
</tr>
<tr>
<td>Lead authors</td>
<td>Daniela E. DiMarco, MD, MPH; Marguerite A. Urban, MD</td>
</tr>
<tr>
<td>Writing group</td>
<td>Steven M. Fine, MD, PhD; Rona M. Vail, MD; Joseph P. McGowan, MD, FACP, FIDSA; Samuel T. Merrick, MD; Asa E. Radix, MD, MPH, PhD; Jessica Rodrigues, MS; Charles J. Gonzalez, MD; Christopher J. Hoffmann, MD, MPH</td>
</tr>
<tr>
<td>Author and writing group</td>
<td>None</td>
</tr>
<tr>
<td>conflict of interest disclosures</td>
<td>None</td>
</tr>
<tr>
<td>Committee</td>
<td>Medical Care Criteria Committee</td>
</tr>
<tr>
<td>Developer and funder</td>
<td>New York State Department of Health AIDS Institute (NYSDOH AI)</td>
</tr>
<tr>
<td>Development process</td>
<td>See Supplement: Guideline Development and Recommendation Ratings</td>
</tr>
</tbody>
</table>
| Related NYSDOH AI guidelines | - Rapid ART Initiation  
- PrEP to Prevent HIV and Promote Sexual Health  
- Immunizations for Adults With HIV |
Purpose of This Guideline

This guideline on the use of doxycycline post-exposure prophylaxis (doxy-PEP) for prevention of bacterial sexually transmitted infections (STIs), including syphilis, chlamydia, and gonorrhea, was developed by the New York State Department of Health AIDS Institute (NYSDOH AI) Clinical Guidelines Program to support clinicians in caring for adults and adolescents with and without HIV who are at risk of STIs. The goals of this guideline are to:

- Summarize the available evidence regarding the use of doxy-PEP for preventing syphilis, chlamydia, and gonorrhea infections
- Provide evidence-based clinical recommendations for the use of doxy-PEP
- Present practical considerations for prescribing doxy-PEP

The literature on this topic is evolving rapidly, with several clinical trials ongoing. To prepare this guideline, the authors conducted a review of the published literature through MEDLINE, conference presentations, and existing published guidance within the United States and internationally.

Biomedical Prevention of STIs

❌ RECOMMENDATIONS

Biomedical Prevention of STIs

- Clinicians should offer doxy-PEP to cisgender men and transgender women who are taking HIV PrEP or receiving HIV care and 1) engage in condomless sex with partner(s) assigned male sex at birth and 2) have had a bacterial STI diagnosed within the past year and are at ongoing risk of STI exposure. (A1)
The United States, including New York State, continues to see high rates of reportable STIs, specifically syphilis, chlamydia, and gonorrhea, despite decades of public health efforts and prevention strategies aimed at curbing the STI epidemic. Except for the year 2020, in which there was an interruption of in-person care and STI testing related to the COVID-19 pandemic, rates of these reportable STIs have steadily increased since 2015, with some populations disproportionately affected, including men who have sex with men (MSM), young people, and some racial and ethnic minority groups [CDC 2023]. The most recent (2021) STI surveillance data from the Centers for Disease Control and Prevention (CDC) note that reportable STIs continue to disproportionately impact people who identify as Black/African American and American Indian/Alaska Native [CDC 2023], making clear that established STI prevention strategies are insufficient.

Biomedical methods for HIV prevention with HIV PrEP and PEP have been very effective. Researchers identified doxycycline as a candidate for biomedical prevention of STIs. In 2011, Wilson and colleagues used mathematical modeling based on sexual behavior factors to predict doxy-PEP efficacy among MSM in Australia. Assuming 50% uptake and 70% efficacy, the model predicted a 50% reduction in syphilis cases after 1 year and an 85% reduction after 10 years [Wilson, et al. 2011]. Doxycycline is an antibiotic in the tetracycline class approved by the U.S. Food and Drug Administration for the management of many different types of infections [Lexicomp 2023; FDA 2016]. Doxycycline is available in 2 different formulations: hyclate, which is more water soluble, and monohydrate, which is less water soluble so may have fewer gastrointestinal adverse effects. Common uses include treatment of chlamydia, syphilis, respiratory infections, and skin and soft tissue infections. Doxycycline has also been used as both a PrEP and PEP agent for certain bacterial and parasitic infections, including Lyme disease, leptospirosis, and malaria [Grant, et al. 2020]. When used in nonpregnant adults, doxycycline is safe and well tolerated, has excellent oral bioavailability, is low cost, and is widely available. Adverse effects of doxycycline are generally mild, with gastrointestinal symptoms being the most common. Other adverse effects include photosensitivity and esophageal injury. Doxycycline is contraindicated in pregnancy because of potential adverse effects on the fetus [Lexicomp 2023]. Doxycycline is also used safely for prolonged periods for some conditions, including acne [Zaenglein, et al. 2016] and prosthetic joint infections [Osmon, et al. 2013]. These factors make doxycycline a promising prophylactic agent; however, the effects on antimicrobial resistance and the microbiome with widespread use are still under investigation.

Acceptability of Doxycycline for STI Prophylaxis

Several surveys conducted among MSM with STI risk factors have demonstrated interest in and acceptability of a biomedical STI prevention option [Fusca, et al. 2020; Spinelli, et al. 2019; Wilson, et al. 2011]. An online survey in Southern California of 212 community members identifying as MSM and 76 healthcare providers found that acceptance of doxycycline as PEP or PrEP was greater among community members taking HIV PrEP or with a recent STI diagnosis than it was among those not taking HIV PrEP or without a recent STI diagnosis [Park, et al. 2021]. For healthcare providers, a recommendation from the CDC was associated with significantly greater willingness to prescribe doxycycline as PEP/PrEP. All respondents expressed concern regarding antibiotic resistance [Park, et al. 2021]. In the DoxyPEP study reviewed below, acceptability of doxycycline was 88% in the study population of cisgender men and transgender women who have sex with men [Luetkemeyer, et al. 2023].
Surveys conducted in the United Kingdom, the Netherlands, and Australia found that in the absence of established guidelines, antibiotics including doxycycline were being used off-label for STI prophylaxis, particularly by individuals taking HIV PrEP [O’Halloran, et al. 2021; Evers, et al. 2020; Chow and Fairley 2019; Carveth-Johnson, et al. 2018], demonstrating a need for further investigation to guide evidence-based use of doxycycline prophylaxis.

To facilitate shared decision-making with patients, it is important that clinicians are aware of the indications for and how to prescribe and manage doxy-PEP and become familiar with the benefits, risks, and limitations surrounding its use.

**Doxycycline as PEP**

Available evidence on doxycycline prophylaxis to prevent bacterial STIs is limited but increasing. Current data are from randomized clinical trials, observational studies, modeling studies, and surveys on acceptability for use. Studies predominantly included cisgender men and transgender women who have sex with men who were receiving HIV PrEP or in care for HIV infection, were aged 35 years and older, and were White.

In 4 randomized clinical trials comparing doxy-PEP with standard of care (routine STI testing), participants received HIV PrEP or HIV care, and in 3 of the 4 trials participants had a history of ≥1 bacterial STI in the prior year. The study protocols used a 200 mg dose of oral doxycycline taken ideally within 24 hours or up to 72 hours of condomless sex to prevent bacterial STIs. All participants were tested for STIs every 3 months during the study period [Luetkemeyer, et al. 2023; Molina, et al. 2023; Stewart, et al. 2023; Molina, et al. 2018]. In the 3 trials conducted among cisgender men and transgender women who have sex with men, there were significant reductions in chlamydia and syphilis, but results were mixed regarding the efficacy of doxy-PEP in preventing gonococcal infection, likely at least in part due to geographic variability in prevalence of tetracycline resistance in gonococci [Luetkemeyer, et al. 2023; Molina, et al. 2023; Fairley and Chow 2018; Molina, et al. 2018; Siguier and Molina 2018]. In a study that included only cisgender women taking HIV PrEP, doxy-PEP was not effective at preventing bacterial STIs [Stewart, et al. 2023].

A modeling study analyzed data from an LGBTQ-focused health center in the United States to assess the effect of doxy-PEP use on STI incidence among more than 10,000 individuals assigned male sex at birth (including cisgender men, transgender women, and nonbinary individuals) who had male sex partners and STI testing (chlamydia, gonorrhea, or syphilis) on record [Traeger, et al. 2023]. STI incidence was 35.9 per 100 person-years. Modeling demonstrated that, rather than prescribing doxy-PEP based solely on HIV or PrEP engagement, prescribing based on STI history resulted in an efficient strategy that balanced uptake and preventive impact. An approach combining these factors, as was done in the clinical trials, was not modeled in this projection. Seven different strategies for prescribing doxy-PEP over 12 months were modeled. Prescribing to all in the sample, an estimated 71% of gonorrhea, chlamydia, and syphilis cases could have been averted, with a number needed to treat (NNT) of 3.9. Prescribing to individuals with HIV (12%) or who were taking HIV PrEP (52%) could have averted 60% of STI diagnoses in this group, with an NNT of 2.9. With prescribing limited to individuals with an STI diagnosis, the proportion using doxy-PEP was reduced to 38% and would have averted 39% of STI diagnoses, with an NNT of 2.4.

This committee’s recommendations on provision of doxy-PEP are outlined above, and implementation considerations are discussed in the guideline section Practical Considerations for Doxy-PEP Implementation. The eligibility criteria for doxy-PEP use include a history of a bacterial STI in the prior year as was done in the existing research trials. However, other factors are associated with increased risk of STI exposure, including engaging in group sex, engaging in transactional sex, and combining sex and substance use [Workowski, et al. 2021]. An STI risk assessment is an individualized process, and the risk-benefit profile for doxy-PEP is expected to vary based on individual patient factors and community and sexual network prevalence. This individualized assessment is an important aspect of the shared decision-making between patient and clinician.

The recommendation for doxy-PEP use among cisgender men and transgender women who have sex with men is based on the significant reductions in bacterial STIs reported in the 3 clinical trials described in detail below. Although the majority of STIs among these populations are asymptomatic and without complications, the significant decrease in STI occurrence provides potential benefits to individuals and the broader community and likely outweighs the potential harms of doxycycline use. Based on the lack of efficacy reported for doxy-PEP in cisgender women in Kenya [Stewart, et al. 2023], doxy-PEP is not recommended for use in individuals at risk of STIs through receptive vaginal sex, despite pharmacologic data from an unrelated study suggesting adequate tissue and secretion levels for protection [Haaland, et al. 2023].

There are no data evaluating doxy-PEP use among cisgender men with sex partners assigned female sex at birth. However, doxy-PEP use among cisgender men (with female partners) who have similar STI risk factors as the doxy-PEP study populations (i.e., history of STIs, multiple sex partners, high-prevalence populations) could also potentially provide individual and community benefits outweighing the risks of doxycycline use. The NNT and degree of potential protective effect with insertive vaginal sex are unknown. This strategy has the possibility of extending the potential benefits of doxy-PEP use,
Evidence from the DOXYVAC trial: Evidence from the DOXYVAC trial evaluated in this study and is discussed below (see guideline section Antimicrobial Resistance, below). Participants with HIV, doxy-PEP did not significantly reduce incident early syphilis or urethral or pharyngeal chlamydia or \( P < 0.01 \). In subgroup analyses, among participants taking HIV PrEP, the significant risk reduction was maintained for each STI individually, including infections at extragenital sites, except for pharyngeal chlamydia \( P < 0.001 \). Among participants taking HIV PrEP, the relative risk (RR) of any incident STI was 0.34 (95% CI, 0.24-0.46; \( P < 0.001 \)), and the NNT was 4.7, whereas among participants with HIV, the RR for any incident STI was 0.38 (95% CI, 0.24-0.60; \( P < 0.001 \)), and the NNT was 5.3.

Evidence from the IPERGAY trial: The first published evidence on doxy-PEP was derived from a substudy of the ANRS IPERGAY randomized trial of on-demand HIV PrEP among cisgender men and transgender women who have sex with men in France, which demonstrated an approximately 70% reduction in incident chlamydia and syphilis infections but no significant reduction in gonorrhea infections in a population reporting sex practices placing them at high risk of STIs [Molina, et al. 2018]. In this open-label extension, more than 200 participants (cisgender men and transgender women who have sex with men) taking HIV PrEP were randomized to receive doxycycline hyclate 200 mg as a single dose within 24 to 72 hours after condomless sex or no doxy-PEP [Molina, et al. 2018]. Study participants were mostly White, >30 years old, and reported having multiple sex partners (10 in 2 months) and engaging in condomless sex acts (10 in 4 weeks). Participants were instructed not to exceed 3 doses per week; the median number of doxy-PEP doses used per month was 3.4, which was fewer than the number of reported condomless sexual encounters. Of participants, 83% took doxy-PEP within 24 hours of sex. Gastrointestinal adverse effects were reported by more than half of the participants, resulting in 8 discontinuations. Doxy-PEP was associated with significant reductions in the incidence of first STI and, in individual analyses, of incident chlamydia and syphilis infections. For incident gonorrhea, however, there was no significant reduction in the doxy-PEP group, which was attributed to the high prevalence of tetracycline resistance among gonococcal isolates in France [Molina, et al. 2018].

Evidence from the DoxyPEP trial: The open-label randomized DoxyPEP study analyzed data from 501 adult cisgender MSM (96%) and transgender women who have sex with men (4%) who were either taking HIV PrEP (n=360) or had HIV (n=194) and who had a bacterial STI and reported condomless sex with a male partner within the past year. Participants were randomized to receive either doxy-PEP as 200 mg of delayed-release doxycycline hyclate (ideally within 24 hours but no later than 72 hours after condomless sex) or standard of care [Luetkemeyer, et al. 2023]. STI testing was performed every 3 months over 1 year of follow-up. Participants had a high prevalence of baseline bacterial STIs and a median of 9 sex partners in the 3 months before enrollment, and 59% reported substance use. The median participant age was 38 years, and more than 67% were White, 7% were Black, 11% were Asian or Pacific Islander, 15% were multiracial or other, and 30% were Hispanic. The maximum dose of doxycycline was 200 mg within a 24-hour period, and the medication was dispensed at 3-month intervals. The initial doxycycline supply included enough tablets for daily use, and the amount dispensed each quarter was adjusted in follow-up based on frequency of sex and doses used. The DoxyPEP study was stopped early after interim analysis noted a significant protective effect in the intervention arm, and participants in the standard-of-care group were offered doxy-PEP [Luetkemeyer, et al. 2023]. Modified intention-to-treat analysis included participants who completed a median of 9 months of follow-up [Luetkemeyer, et al. 2023]. Gonorrhea was the most common STI diagnosed, and there were very few cases of early syphilis. Median doxy-PEP use was 4 doses per month, with 25% of participants reporting more than 10 doses per month. This study demonstrated a 52% quarterly reduction in any incident STI among participants with HIV (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.28-0.83), and a 66% reduction among those taking HIV PrEP (HR, 0.34; 95% CI, 0.23-0.51) [Luetkemeyer, et al. 2023; Luetkemeyer, et al. 2022; SFDPH 2022]. Among participants taking HIV PrEP, the relative risk (RR) of any incident STI was 0.34 (95% CI, 0.24-0.46; \( P < 0.001 \)), and the NNT was 4.7, whereas among participants with HIV, the RR for any incident STI was 0.38 (95% CI, 0.24-0.60; \( P < 0.001 \)), and the NNT was 5.3.

In subgroup analyses, among participants taking HIV PrEP, the significant risk reduction was maintained for each STI individually, including infections at extragenital sites, except for pharyngeal chlamydia [Luetkemeyer, et al. 2023]. Among participants with HIV, doxy-PEP did not significantly reduce incident early syphilis or urethral or pharyngeal chlamydia or gonorrhea. Doxycycline was well tolerated, and self-reported adherence was high. Antimicrobial resistance was also evaluated in this study and is discussed below (see guideline section Antimicrobial Resistance, below).

Evidence from the DOXYVAC trial: In the phase III randomized 2x2 factorial designed DOXYVAC trial, the efficacy of both doxy-PEP for bacterial STI prophylaxis and meningococcal serotype B vaccination for preventing gonococcal infection was investigated among 446 cisgender men and transgender women who have sex with men taking HIV PrEP in France [Molina, et al. 2023]. Participants were predominantly White, had a median age of 39 years, were long-term HIV PrEP users, reported multiple sex partners, and had multiple prior STIs. Unblinded early interim analysis revealed significant reductions in any incident STI, and participants were all offered doxy-PEP. Doxy-PEP significantly reduced the incidence of the first episode of chlamydia (adjusted HR [aHR], 0.11; 95% CI, 0.04-0.30; \( P < 0.001 \)), syphilis (aHR, 0.21; 95% CI, 0.09-0.47; \( P < 0.001 \)), gonorrhea (aHR, 0.49; 95% CI, 0.32-0.76; \( P < 0.001 \)), and Mycoplasma genitalium (aHR, 0.55; 95% CI, 0.34-0.89; \( P = 0.015 \)) infections. Adherence was also high in this study at approximately 80%, with a median use of 3.5 doses per month and a median time to doxy-PEP intake after sex of 27 hours. Additionally, antimicrobial resistance was analyzed and is discussed below (see guideline section Antimicrobial Resistance, below).
Doxy-PEP and receptive vaginal sex: Preliminary data from a randomized trial in Kisumu, Kenya, that compared doxy-PEP with the standard of care among cisgender women who were 18 to 30 years old and taking HIV PrEP found that doxy-PEP was not effective for bacterial STI prevention in this population [Stewart, et al. 2023]. The study enrolled 449 participants from 2020 to 2022, with very little loss to follow-up. At baseline, 18% of participants were diagnosed with an STI (14% with chlamydia, 4% with gonorrhea, and <1% with syphilis). Data on doxy-PEP adherence were self-reported, with 78% of condomless sex encounters covered. Incident STIs were similar between groups (annual incidence of 27%), with no significant reduction in the doxy-PEP group. No incident HIV infections were reported. The reason for the lack of demonstrable efficacy of doxy-PEP in this study is unclear. Possible factors influencing these results include the prevalence of high-level tetracycline resistance among gonococcal isolates in Kenya [Soge, et al. 2023], adherence being less than what was ascertained by self-report, and biologic or anatomic differences. An unrelated study in the United States evaluated drug concentrations with event-driven oral dosing and showed that 200 mg of doxycycline hyclate achieved concentrations above minimum inhibitory concentrations (MICs) for syphilis, chlamydia, and gonorrhea in rectal, vaginal, and cervical tissues as well as rectal and vaginal secretions; these concentrations were sustained at least 2 days after dosing, although the degree above MIC was much lower for Neisseria gonorrhoeae [Haaland, et al. 2023]. Higher doxycycline concentrations were sustained for a longer duration in rectal secretions than in vaginal secretions, although the levels remained above the MIC.

Doxy-PEP has not been studied in gender-diverse populations at risk of STIs through receptive vaginal sex.

<table>
<thead>
<tr>
<th>KEY POINTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Doxy-PEP is not 100% effective in preventing bacterial STIs and has varying degrees of efficacy in preventing gonorrhea, chlamydia, and syphilis overall and by anatomic site.</td>
</tr>
<tr>
<td>• Doxy-PEP is not recommended to protect against STI acquisition through receptive vaginal sex.</td>
</tr>
<tr>
<td>• It is essential to provide counseling and education to patients on the limitations of doxy-PEP and to emphasize that ongoing condom use and engagement in sexual health services is necessary, including but not limited to routine STI screening, STI testing for symptomatic patients, and STI treatment or evaluation after an STI exposure.</td>
</tr>
<tr>
<td>• Evaluation by a clinician after a known or possible STI exposure is necessary to determine whether treatment is needed.</td>
</tr>
<tr>
<td>• For individuals using doxy-PEP who are diagnosed with gonorrhea, chlamydia, or syphilis, treat according to the recommendations in the CDC STI Treatment Guidelines.</td>
</tr>
</tbody>
</table>

Antimicrobial Resistance

Published research, previous guideline statements, and editorials have raised concerns about the impact of doxy-PEP on the emergence of antimicrobial resistance for bacterial STIs and other non-STI pathogens with widespread long-term use [Cornelisse, et al. 2023; Luetkemeyer, et al. 2023; Molina, et al. 2023; Kohli, et al. 2022; Lewis 2022; Luetkemeyer, et al. 2022; Grant, et al. 2020; Molina, et al. 2018; Siguier and Molina 2018; Golden and Handsfield 2015]. Increasing antimicrobial resistance is a concern at both the individual and population levels [Cornelisse, et al. 2023]. It may take years to determine this effect, and additional research is needed [Siguier and Molina 2018]. To date, studies of doxy-PEP have not found detectable resistance in Treponema pallidum or Chlamydia trachomatis strains [Cornelisse, et al. 2023]. Doxycycline resistance is already a concern for other bacterial STIs, including M. genitalium and N. gonorrhoeae, and there are few alternative therapeutic options for M. genitalium [Workowski, et al. 2021]. Tetracycline (used as a surrogate for doxycycline) resistance in N. gonorrhoeae isolates varies geographically and is reported at 20.6% nationwide by the CDC Gonococcal Isolate Surveillance Project [CDC 2023]. Doxycycline is an important antibiotic used to treat non-sexually transmitted infections when other oral treatment options are severely limited, including methicillin-resistant Staphylococcus aureus (MRSA). Doxycycline also remains an option for antimicrobial-resistant gonococcal infections if susceptibility is confirmed. The benefits of widespread use of doxycycline must be weighed against the known and potential risks of selecting for antimicrobial resistance and altering the various microbiomes (e.g., gastrointestinal, vaginal, skin). In an analysis of more than 2,000 gonococcal isolates in Europe, the presence of 2 common tetracycline-associated mutations was strongly associated with additional mutations conferring cross-resistance to other antibiotics, including beta-lactams, macrolides, and fluoroquinolones [Vanbaelen, et al. 2023]. This raises concern that selecting for gonorrhea tetracycline resistance may also impact the effectiveness of other antibiotic classes, including cephalosporins, which are the standard of care for gonorrhea treatment.

To assess the impact of doxy-PEP use on antimicrobial resistance, nares and oropharynx specimens were examined for S. aureus in the DoxyPEP study [Luetkemeyer, et al. 2023], and tetracycline resistance in extended-spectrum beta-lactamase (ESBL) Escherichia coli (as a marker of microbiome influence) and MRSA were assessed in the DOXYVAC study [Molina, et al.
In the DoxyPEP study, cultures were available for 17.2% of gonorrhea infections (n=44) [Luetkemeyer, et al. 2023]. Of these, baseline tetracycline resistance (a surrogate for doxycycline resistance) was 27%. After enrollment, resistance was 38% in the doxycycline groups and 12% in the standard-of-care groups, and doxy-PEP appeared less protective for tetracycline-resistant gonorrhea, although the sample size was small [Luetkemeyer, et al. 2023; Luetkemeyer, et al. 2022]. S. aureus was cultured from the oronasopharynx in 45% of participants, and baseline doxycycline resistance was 12% [Luetkemeyer, et al. 2023]. At 1 year, S. aureus colonization identified by culture was significantly less in the doxy-PEP groups than the standard-of-care groups, and prevalence of doxycycline-resistant isolates was 16% in the doxycycline groups and 8% in the standard-of-care groups [Luetkemeyer, et al. 2023]. In the DOXYVAC study, cultures were available for 15% of gonorrhea infections [Molina, et al. 2023]. Baseline tetracycline resistance was 100%, and the prevalence of high-level resistance was greater in the doxy-PEP group (33.3%) than in the standard-of-care group (18.9%). As markers for assessing the impact of doxy-PEP on the microbiome, there was no significant difference in detection of ESBL E. coli from anal swabs or MRSA from the pharynx.

Based on these data, the efficacy of doxy-PEP for gonorrhea is expected to differ depending on the prevalence of tetracycline resistance in a given population or geographic region. For S. aureus, doxy-PEP is associated with increased resistance [Luetkemeyer, et al. 2023], which is an important consideration in the preservation of antimicrobial treatment options for MRSA infection.

Recommendations Outside of New York State

Several organizations have issued guidance regarding the use of doxy-PEP [CDC 2023; CDPH 2023; Cornelisse, et al. 2023; Gandhi, et al. 2023; NCSD 2023; PHSKC 2023; SCPHD 2023; Kohli, et al. 2022; SFDPH 2022]. There is significant variability regarding implementation of this intervention, although dosing recommendations have been uniformly consistent with the dosing used in the studies to date.

United Kingdom and Australian guidelines did not recommend doxy-PEP implementation [Cornelisse, et al. 2023; Kohli, et al. 2022], but position statements have summarized the available evidence (including risks and benefits) to provide some clinical guidance when patients are seeking or already taking doxycycline prophylaxis. The British Association for Sexual Health and HIV and the UK Health Security Agency do not endorse the use of doxycycline as prophylaxis, primarily because of concerns regarding antimicrobial resistance and limited long-term data [Kohli, et al. 2022]. The Australian Society for HIV, Viral Hepatitis, and Sexual Health Medicine does not recommend for or against doxy-PEP but advises clinicians to consider the risks and benefits at the individual and population levels, with a focused discussion of concerns with widespread use including the potential for selection of antimicrobial resistance and impact on the microbiome [Cornelisse, et al. 2023].

At the time of this writing, the CDC has not formally recommended for or against doxycycline use for bacterial STI prophylaxis [CDC 2023]. In 2022, based on preliminary data from the DoxyPEP study, the CDC updated its STI treatment guidelines to include a brief summary of the available evidence on doxy-PEP and recommend that, if prescribed as PEP, 200 mg of oral doxycycline be taken within 24 to 72 hours after sex (as in the DoxyPEP study protocol) and that patients be provided with education and counseling regarding the risks [CDC 2023]. In their 2022 recommendations, the International Antiviral Society-USA recommended that until more data are available, doxy-PEP should be considered on a case-by-case basis for individuals at elevated risk of these bacterial STIs [Gandhi, et al. 2023].

The San Francisco Department of Public Health (SFDPH) released implementation guidance in October 2022 recommending doxy-PEP for cisgender men and transgender women who meet 2 eligibility criteria outlined in the DoxyPEP study: 1) have a diagnosis of a bacterial STI within the last year, and 2) report condomless sex with at least 1 male partner in the past year [SFDPH 2022]. The SFDPH also recommends offering doxy-PEP via shared decision-making to cisgender men, transgender men, and transgender women who have had multiple sex partners assigned male sex at birth within the past year, even in the absence of a prior STI diagnosis. Additionally, the SFDPH recommends comprehensive sexual health services that include routine STI testing, and counseling patients on the known and potential effects of doxy-PEP use on antimicrobial resistance and the microbiome, efficacy data on and limitations of doxy-PEP, and potential adverse effects. The SFDPH dosing and prescribing recommendations are the same as those used in the DoxyPEP study; however, the SFDPH notes that immediate- or extended-release doxycycline could be used, although the extended-release formulation may be more expensive. The California Department of Health (CDPH) sent out a Dear Colleague Letter on April 28, 2023, with recommendations on doxy-PEP [CDPH 2023]. The CDPH recommends doxy-PEP for cisgender men or transgender women with ≥1 bacterial STI in the past 12 months and suggests offering doxy-PEP via shared decision-making to all nonpregnant individuals at increased risk of STI acquisition, even if there is no history of an STI diagnosis. Similar to San Francisco, the CDPH also recommends including comprehensive sexual health counseling and education.

In June 2023, the King County Sexual Health Clinic in Seattle, Washington, released doxy-PEP guidelines recommending that clinicians engage in shared decision-making on doxy-PEP with cisgender men and transgender women with history of an STI
in the past year and ongoing sex encounters with partners assigned male sex at birth [PHSKC 2023]. Their guidance recommends stronger consideration for those in this population with a specific history of syphilis or multiple STIs in the prior year, and also that clinicians may consider prescribing doxy-PEP episodically when patients anticipate their STI exposure risk to be elevated (using group sex events as an example).

The National Coalition of STD Directors released a doxy-PEP implementation toolkit with basic guidance on community engagement, workflow, education, program evaluation, and prescribing logistics [NCSD 2023]. Highlights from the toolkit emphasize ensuring equitable criteria for offering doxy-PEP and reducing unnecessary access restrictions.

**Practical Considerations for Doxy-PEP Implementation**

As with any drug therapy, a review of the patient’s health history, current medications, and allergies to ensure there are no health concerns, drug-drug interactions, or medication allergies that would preclude use is indicated before initiating doxycycline post-exposure prophylaxis (doxy-PEP). Concurrent use of doxy-PEP with daily doxycycline or tetracycline for other conditions is contraindicated. Medications other than doxycycline have not been studied for bacterial sexually transmitted infection (STI) PEP. When doxycycline is not tolerated or contraindications to its use exist, doxy-PEP is not recommended. Practical considerations for prescribing and monitoring doxy-PEP are outlined in Table 1, below.

**Table 1: Considerations for Doxy-PEP Implementation**

<table>
<thead>
<tr>
<th>Consideration(s)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Available formulations</td>
<td>• Doxycycline hyclate delayed-release 200 mg oral tablet</td>
</tr>
<tr>
<td></td>
<td>• Doxycycline hyclate or monohydrate immediate-release 100 mg oral capsule or tablet (2 capsules or tablets taken together for a total of 200 mg)</td>
</tr>
<tr>
<td></td>
<td>• The immediate-release formulations are more widely available and usually cost less than the delayed-release formulation.</td>
</tr>
<tr>
<td>Administration</td>
<td>• As doxy-PEP, 200 mg of doxycycline should ideally be taken within 24 hours after condomless sex, up to 72 hours maximum.</td>
</tr>
<tr>
<td></td>
<td>• No more than 200 mg of doxycycline should be taken in a 24-hour period.</td>
</tr>
<tr>
<td></td>
<td>• Milk and vitamins containing positive cations (e.g., calcium, zinc, magnesium) should be avoided within 2 hours of taking doxycycline, because these interfere with doxycycline absorption and may lower doxycycline levels, potentially reducing efficacy.</td>
</tr>
<tr>
<td>Contraindications, drug-drug interactions, and dose adjustments</td>
<td>• Doxycycline should not be used as PEP concurrently with other doxycycline therapy (or any other tetracycline-class antibiotic) for treatment or prevention of a health condition (e.g., acne, rosacea, malaria prophylaxis).</td>
</tr>
<tr>
<td></td>
<td>• No significant drug-drug interactions exist between doxycycline and ARVs used for HIV treatment or PrEP.</td>
</tr>
<tr>
<td></td>
<td>• No known drug reactions exist between doxycycline and gender-affirming hormone therapies.</td>
</tr>
<tr>
<td></td>
<td>• No doxycycline dose adjustments are indicated for patients with renal dysfunction.</td>
</tr>
<tr>
<td></td>
<td>• Doxycycline is generally contraindicated during pregnancy because of potential adverse effects on the fetus [FDA 2016].</td>
</tr>
<tr>
<td>Adverse effects</td>
<td>• GI adverse effects are common; taking doxycycline with food may help alleviate nausea or GI upset. Symptoms including nausea, vomiting, and reflux can be severe enough to require cessation of doxycycline.</td>
</tr>
<tr>
<td></td>
<td>• Esophageal injury and irritation can occur. Doxycycline should be taken with an 8-oz glass of water and the individual should remain upright for 30 minutes to 1 hour after dosing.</td>
</tr>
<tr>
<td></td>
<td>• Skin photosensitivity and phototoxicity can occur; wearing sunscreen, limiting sun exposure, and avoiding tanning beds can help prevent sunburn and other skin injury.</td>
</tr>
<tr>
<td></td>
<td>• Intracranial hypertension is a rare but serious adverse effect. Refractory headaches or vision changes should be evaluated promptly by a clinician.</td>
</tr>
<tr>
<td></td>
<td>• Doxycycline use may select for antibiotic-resistant organisms, which can cause infections in some circumstances and can disrupt the microbiome.</td>
</tr>
</tbody>
</table>
Table 1: Considerations for Doxy-PEP Implementation

<table>
<thead>
<tr>
<th>Consideration(s)</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Supply of doxy-PEP medications                         | • For patients taking HIV PrEP, consider prescribing a doxy-PEP supply equal to the supply of HIV PrEP medications for patient convenience (e.g., 90 days).  
• For patients not taking HIV PrEP, a 90-day supply is suggested.  
• Regarding dose quantity:  
  ‒ For delayed-release doxycycline 200 mg tablets, the quantity dispensed should not exceed 90 doses per 3 months.  
  ‒ For immediate-release 100 mg capsules or tablets, the quantity dispensed should not exceed 180 doses per 3 months.  
  ‒ The quantities above are the maximum number to be dispensed; many patients will not need such a large quantity. Shared decision-making can determine the lowest quantity needed based on the frequency of condomless sexual encounters during a 3-month interval. |
| Follow-up and laboratory monitoring                    | • Engage patients taking doxy-PEP in ongoing comprehensive sexual health services that include STI screening, HIV PrEP, immunizations, and other health promotion strategies as indicated [a].  
• At least every 3 months:  
  ‒ Screen for syphilis, HIV if not previously diagnosed, gonorrhea, and chlamydia (including extragenital testing when indicated), ensuring that tests have been obtained before providing a doxy-PEP prescription refill.  
  ‒ Offer HIV PrEP or HIV treatment as needed.  
  ‒ Assess for ongoing doxy-PEP needs and continue in shared decision-making as new evidence becomes available.  
• The doxycycline package insert advises periodic monitoring of hepatic function, renal function (specifically BUN), and CBC with prolonged therapy. It is currently unclear whether this routine monitoring is necessary for doxy-PEP [b]. |
| Key points for patient education                       | • Medication administration instructions and contraindications: See above.  
• Protective effect: Doxy-PEP is not 100% effective and is not effective against all STIs. For cisgender men and transgender women at risk of STIs who were engaged in routine sexual healthcare, doxy-PEP reduced the likelihood of an STI diagnosis by >50%. Evaluation by a clinician after a possible STI exposure is necessary to determine whether treatment is needed.  
• Adverse effects: Doxycycline can cause GI adverse effects, photosensitivity, and esophageal irritation, which can be mitigated using strategies noted above. Long-term doxycycline use may increase the risk of developing an antibiotic-resistant infection. The potential long-term effects of doxy-PEP use are not known at this time.  
• Ongoing screening: Screening for STIs every 3 months is necessary while taking doxy-PEP. Routine HIV testing should continue in individuals at risk of HIV. Yearly blood tests (CBC, liver and kidney tests) are recommended to monitor for potential adverse antibiotic effects. |

Abbreviations: ARV, antiretroviral medication; BUN, blood urea nitrogen; CBC, complete blood count; doxy-PEP, doxycycline post-exposure prophylaxis; GI, gastrointestinal; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.

Notes:
  a. See the Centers for Disease Control and Prevention STI Treatment Guidelines and the NYSDOH AI guidelines PrEP to Prevent HIV and Promote Sexual Health and Immunizations for Adults With HIV.  
  b. The DoxyPEP study protocol included yearly monitoring of these tests, informing the currently recommended strategy.

Treat any patient diagnosed with gonorrhea, chlamydia, or syphilis while taking doxy-PEP according to the Centers for Disease Control and Prevention (CDC) STI Treatment Guidelines [Workowski, et al. 2021].

For patients taking doxy-PEP who present for care after a sexual partner(s) is diagnosed with chlamydia or gonorrhea, a clinical evaluation that includes STI testing with a shared decision-making approach regarding presumptive treatment is the suggested approach. Acknowledging that doxy-PEP is not 100% effective, CDC guidance recommends presumptive treatment for patients exposed to chlamydia or gonorrhea within the past 60 days, regardless of test results [Workowski, et al. 2021]. An alternative option for those who decline presumptive treatment is to administer treatment based on test results and continue STI screening every 3 months.

Patients taking doxy-PEP who are exposed to early syphilis within the prior 90 days can also be treated presumptively per the CDC STI Treatment Guidelines [Workowski, et al. 2021] regardless of test results. If treatment is declined, repeat syphilis testing at 3 months is necessary due to the potential for an extended period of syphilis incubation.
All Recommendations

☑ ALL RECOMMENDATIONS: DOXYCYCLINE POST-EXPOSURE PROPHYLAXIS TO PREVENT BACTERIAL SEXUALLY TRANSMITTED INFECTIONS

Biomedical Prevention of STIs

- Clinicians should offer doxy-PEP to cisgender men and transgender women who are taking HIV PrEP or receiving HIV care and 1) engage in condomless sex with partner(s) assigned male sex at birth and 2) have had a bacterial STI diagnosed within the past year and are at ongoing risk of STI exposure. (A1)
- Clinicians should offer doxy-PEP to cisgender men and transgender women who are not taking HIV PrEP or receiving HIV care and 1) engage in condomless sex with partner(s) assigned male sex at birth and 2) have had a bacterial STI diagnosed within the past year and are at ongoing risk of STI exposure. (A2†)
- Clinicians should engage in shared decision-making with cisgender men who 1) engage in condomless sex with multiple partners assigned female sex at birth and 2) have had a bacterial STI diagnosed within the past year, offering doxy-PEP on a case-by-case basis. (B3)
- When prescribing doxy-PEP, clinicians should use the dosing regimen of oral doxycycline 200 mg taken ideally within 24 to 72 hours of condomless sex (A1) and counsel patients (A*) on the key points for patient education outlined in Table 1: Considerations for Doxy-PEP Implementation.
- For individuals taking doxy-PEP, clinicians should screen for HIV, chlamydia, gonorrhea, and syphilis at least every 3 months. (A1)
- Clinicians should offer HIV PrEP to individuals who do not have HIV and are initiating or using doxy-PEP. (A*)
- Clinicians should offer HIV treatment to individuals with HIV who are not on antiretroviral therapy and are initiating or using doxy-PEP. (A1)

Abbreviations: doxy-PEP, doxycycline post-exposure prophylaxis; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.

References


FDA. Doxycycline hyclate delayed-release tablets, for oral use. 2016 Apr. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/90431Orig1s010lbl.pdf [accessed 2023 June 12]


Molina JM, Bercot B, Assoumou L, et al. ANRS 174 DOXYVAC: an open-label randomized trial to prevent STIs in MSM on PrEP. Abstract 119. CROI; 2023 Feb 19-22; Seattle, WA.  


NCSD. Doxycycline for STI PEP implementation toolkit. 2023 Jul.  


PHSKC. Doxycycline post-exposure prophylaxis (doxy-PEP) to prevent bacterial STIs in men who have sex with men (MSM) and transgender persons who have sex with men. 2023.  

SCPHD. Doxycycline use as post-exposure prophylaxis to prevent bacterial sexually transmitted infections. 2023 Mar 20.  


Supplement: Guideline Development and Recommendation Ratings

<table>
<thead>
<tr>
<th>Table S1: Guideline Development: New York State Department of Health AIDS Institute Clinical Guidelines Program</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Developer</strong></td>
</tr>
<tr>
<td><strong>Funding source</strong></td>
</tr>
<tr>
<td><strong>Program manager</strong></td>
</tr>
<tr>
<td><strong>Mission</strong></td>
</tr>
<tr>
<td><strong>Expert committees</strong></td>
</tr>
</tbody>
</table>
| **Committee structure** | - Leadership: AI-appointed chair, vice chair(s), chair emeritus, clinical specialist(s), JHU Guidelines Program Director, AI Medical Director, AI Clinical Consultant, AVAC community advisor  
- Contributing members  
- Guideline writing groups: Lead author, coauthors if applicable, and all committee leaders |
| **Disclosure and management of conflicts of interest** | - Annual disclosure of financial relationships with commercial entities for the 12 months prior and upcoming is required of all individuals who work with the guidelines program, and includes disclosure for partners or spouses and primary professional affiliation.  
- The NYSDOH AI assesses all reported financial relationships to determine the potential for undue influence on guideline recommendations and, when indicated, denies participation in the program or formulates a plan to manage potential conflicts. Disclosures are listed for each committee member. |
| **Evidence collection and review** | - Literature search and review strategy is defined by the guideline lead author based on the defined scope of a new guideline or update.  
- A comprehensive literature search and review is conducted for a new guideline or an extensive update using PubMed, other pertinent databases of peer-reviewed literature, and relevant conference abstracts to establish the evidence base for guideline recommendations.  
- A targeted search and review to identify recently published evidence is conducted for guidelines published within the previous 3 years.  
- Title, abstract, and article reviews are performed by the lead author. The JHU editorial team collates evidence and creates and maintains an evidence table for each guideline. |
| **Recommendation development** | - The lead author drafts recommendations to address the defined scope of the guideline based on available published data.  
- Writing group members review the draft recommendations and evidence and deliberate to revise, refine, and reach consensus on all recommendations.  
- When published data are not available, support for a recommendation may be based on the committee’s expert opinion.  
- The writing group assigns a 2-part rating to each recommendation to indicate the strength of the recommendation and quality of the supporting evidence. The group reviews the evidence, deliberates, and may revise recommendations when required to reach consensus. |
Table S1: Guideline Development: New York State Department of Health AIDS Institute Clinical Guidelines Program

<table>
<thead>
<tr>
<th>Review and approval process</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Following writing group approval, draft guidelines are reviewed by all contributors, program liaisons, and a volunteer reviewer from the AI Community Advisory Committee.</td>
</tr>
<tr>
<td>• Recommendations must be approved by two-thirds of the full committee. If necessary to achieve consensus, the full committee is invited to deliberate, review the evidence, and revise recommendations.</td>
</tr>
<tr>
<td>• Final approval by the committee chair and the NYSDOH AI Medical Director is required for publication.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>External reviews</th>
</tr>
</thead>
<tbody>
<tr>
<td>• External review of each guideline is invited at the developer’s discretion.</td>
</tr>
<tr>
<td>• External reviewers recognized for their experience and expertise review guidelines for accuracy, balance, clarity, and practicality and provide feedback.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Update process</th>
</tr>
</thead>
<tbody>
<tr>
<td>• JHU editorial staff ensure that each guideline is reviewed and determined to be current upon the 3-year anniversary of publication; guidelines that provide clinical recommendations in rapidly changing areas of practice may be reviewed annually. Published literature is surveilled to identify new evidence that may prompt changes to existing recommendations or development of new recommendations.</td>
</tr>
<tr>
<td>• If changes in the standard of care, newly published studies, new drug approval, new drug-related warning, or a public health emergency indicate the need for immediate change to published guidelines, committee leadership will make recommendations and immediate updates and will invite full committee review as indicated.</td>
</tr>
</tbody>
</table>

Table S2: Recommendation Ratings and Definitions

<table>
<thead>
<tr>
<th>Strength</th>
<th>Quality of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A: Strong</td>
<td>1 Based on published results of at least 1 randomized clinical trial with clinical outcomes or validated laboratory endpoints.</td>
</tr>
<tr>
<td>B: Moderate</td>
<td>* Based on either a self-evident conclusion; conclusive, published, in vitro data; or well-established practice that cannot be tested because ethics would preclude a clinical trial.</td>
</tr>
<tr>
<td>C: Optional</td>
<td>2 Based on published results of at least 1 well-designed, nonrandomized clinical trial or observational cohort study with long-term clinical outcomes.</td>
</tr>
<tr>
<td></td>
<td>2† Extrapolated from published results of well-designed studies (including nonrandomized clinical trials) conducted in populations other than those specifically addressed by a recommendation. The source(s) of the extrapolated evidence and the rationale for the extrapolation are provided in the guideline text. One example would be results of studies conducted predominantly in a subpopulation (e.g., one gender) that the committee determines to be generalizable to the population under consideration in the guideline.</td>
</tr>
<tr>
<td></td>
<td>3 Based on committee expert opinion, with rationale provided in the guideline text.</td>
</tr>
</tbody>
</table>